Objective
To determine if a cardiovascular disease prevention (CVD) counseling program for lupus patients decreases the prevalence of CVD risk factors.
Methods
The assessment phase of three-year CVD prevention counseling program included the evaluation of CVD risk factors, diet, exercise habits, and medications. The education phase included discussion of the above risk factors as well as CVD and thrombosis prevention strategies. Patients were prospectively followed every 3–6 months for risk assessment and continued education by a nurse practitioner and a medical doctor.
Results
Between March 2009 and December 2014, 121 patients were included. At baseline, abnormal blood pressure, blood glucose, cholesterol profile, and body mass index were found in 50 (41%), 7 (6%), 82 (68%), and 77 (64%) of patients, respectively. During the three-year follow-up, among those with abnormal baseline values: a) prevalence of abnormal blood pressure significantly decreased (OR: 0.94, 95% CI: 0.92–0.96, p<0.0001) with significant mean systolic blood pressure improvement (−6.12 ± 2.16 mmHg, p<0.05); b) prevalence of abnormal cholesterol profile significantly decreased (OR: 0.90; 95% CI: 0.92–0.96) with significant improvements in mean high-density lipoprotein (+5.4 ± 0.36 mg/dl, p<0.0001) and mean triglyceride levels (−12.6 ± 0.81 mg/dl, p<0.05); and c) no significant change in blood glucose and body mass index were observed. At baseline, 100 (83%) and 95 (79%) patients had poor diet and physical activity; during the follow-up, both significantly improved in the entire population.
Conclusion
Our data suggest that a CVD prevention counseling program decreases the prevalence of some CVD risk factors in lupus patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.